Premium
A Light‐Driven Anti‐Cancer Dual‐Therapeutic Cassette Enhances Solid Tumour Regression
Author(s) -
Kim A Ra,
Shin Seung Won,
Cho SeungWoo,
Lee Joo Young,
Kim DongIk,
Um Soong Ho
Publication year - 2013
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.201200471
Subject(s) - cancer , drug , cancer research , cancer cell , doxorubicin , in vivo , prostate cancer , computational biology , biology , medicine , pharmacology , chemotherapy , microbiology and biotechnology
The majority of anticancer therapeutics have failed to control the target cancers. Thus, new rational design concepts are critical. In most of the biological reactions, a cascade pathway is used to activate appropriate responses. In the cascade pathway, a small signal derived from neighboring environments can be amplified and it further triggers overwhelming and specialized responses. It can be applied to achieve powerful therapeutic effects for novel drug design strategies. Inspired by this concept, we design a preferential dual anti‐cancer therapeutic cassette composed of (i) DNA/RNA nanostructures as both anticancer containers and target ligands and (ii) a gold nanocrystal as localized heat inducers. We demonstrate that this multi‐modular platform is superior to conventional cancer medications in that it had higher drug loading efficiency, tunable drug release, and intrinsic serum stability characteristics. Both doxorubicin chemotherapy and thermal ablation exert a powerful synergistic killing effect that resulted in prostate cancer regression both in vitro and in vivo. We speculate that our novel anti‐cancer drug system can be adapted to effectively destroy many different types of solid cancers.